Bispecifics and multispecifics at Antibody Engineering 2026

Dec 13–16, 2026 San Diego, CA ~900 attendees Website

40 organizations at Antibody Engineering 2026 present work in bispecifics & multispecifics: 22 drug developers, 10 suppliers and service providers and 8 academic, government and non-profit bodies. Between them they bring 68 presentations to the program. Most represented: Xencor (4 on the program), AstraZeneca (3 on the program), Amgen (3 on the program). As of Nov 10, 2026.

All 168 organizations at Antibody Engineering 2026 →

Format
Top represented
Showing 1–10 of 40 organizations
OrganizationAntibody Engineering 2026 Attendance
Xencor
Pasadena, CA
Biotech
Develops engineered antibodies using its XmAb Fc and bispecific technologies, for cancer and autoimmune diseases.
Chair
Sun Dec 13
1:00pm–1:15pm
Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen
Talk
Sun Dec 13
4:15pm–5:00pm
Moderated Panel Discussion with Session Speakers
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen
Chair
Mon Dec 14
8:00am–8:05am
Co-Chairs' Welcome and Opening Remarks
Keynote Presentations - Livestream · with Gyes
Talk
Mon Dec 14
10:55am–11:30am
Jim Huston Science Talent Award and Presentation
Keynote Presentations - Livestream · with Dana-Farber Cancer Institute, Johnson & Johnson
Chair
Wed Dec 16
8:10am–8:15am
Co-Chairs’ Remarks
Track 2: Engineering Antibody Interfaces: Unlocking New Biology · with Dualitas Therapeutics
Talk
Wed Dec 16
9:15am–9:45am
XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life
Redesigned antibody arms that pair only with their intended partner, used to build two-target antibodies that last longer in blood.
Bispecifics & multispecifics
AstraZeneca
Cambridge, United Kingdom
Large pharma
Global pharmaceutical company developing antibodies, antibody-drug conjugates and multispecifics in oncology and other diseases.
Talk
Sun Dec 13
11:00am–11:45am
Career Path/Experiences Panel Discussion
Early Career Scientist Session · with Macaw Therapeutics, Genentech, Adaxion Therapeutics
Keynote
Mon Dec 14
10:20am–10:55am
From Insight to Impact: Translational Medicine as a Driver of ADC Clinical Success and Future Innovation
Why finding biological markers of response early helps antibodies carrying a cell-killing drug succeed in patients.
ADCs & conjugates
Talk
Wed Dec 16
10:30am–11:00am
CD8-Guided T Cell Engager with Potent Preclinical Efficacy and Superior Therapeutic Index
An antibody that pulls killer T cells onto liver cancer cells while rousing fewer of the T cells that drive dangerous immune reactions.
Chair
Wed Dec 16
2:10pm–2:15pm
Co-Chairs' Remarks
Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms · with Washington University School of Medicine
Talk
Wed Dec 16
2:15pm–2:45pm
Expanding the Toolbox: Non-natural Amino Acids Enable Development of a CD30 Dual-payload ADC
Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
Amgen
Thousand Oaks, CA
Large pharma
Global biopharmaceutical company developing and manufacturing biologic medicines, including bispecific T-cell engagers.
Chair
Sun Dec 13
1:00pm–1:15pm
Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor
Talk
Sun Dec 13
1:15pm–1:45pm
Developability-Guided Generative Biology for Therapeutic Protein Engineering
Designing new therapeutic proteins by computer while checking from the start that they can be made and purified.
AI & computational design
Talk
Sun Dec 13
4:15pm–5:00pm
Moderated Panel Discussion with Session Speakers
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor
Talk
Mon Dec 14
5:45pm–6:15pm
Induced Proximity and Next-Generation Antibody Therapeutics
Track 2: Engineering Solutions for Accessing Difficult Targets
Bispecifics & multispecifics
Genentech
South San Francisco, CA
Large pharma
Biotechnology company and Roche Group member that discovers, develops and markets antibody and other medicines.
Talk
Sun Dec 13
11:00am–11:45am
Career Path/Experiences Panel Discussion
Early Career Scientist Session · with Macaw Therapeutics, AstraZeneca, Adaxion Therapeutics
Talk
Mon Dec 14
2:30pm–3:00pm
Dissecting the Mechanisms of Action of PROTABs: Insights into Designing Antibody-Based Protein Degraders
How the shape of antibody binding decides whether a target protein on the cell surface is actually destroyed.
Bispecifics & multispecifics
Chair
Tue Dec 15
8:10am–8:15am
Co-Chairs’ Remarks
Track 1: Advanced In Vivo Approaches to Antibody Discovery · with Johnson & Johnson
Talk
Tue Dec 15
8:15am–8:45am
From COVID to Cancer: LNP-mRNA as an Antigen Format for Antibody Discovery Against Challenging Membrane Proteins
Immunizing animals with mRNA packaged in tiny fat particles, so their antibodies recognize proteins embedded in cell membranes.
Protein engineering
Regeneron
Tarrytown, NY
Large pharma
Biotechnology company that discovers, develops and markets antibody medicines, including bispecific antibodies, using its VelocImmune mouse platform.
Talk
Sun Dec 13
3:45pm–4:15pm
From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics
How measurements of drug levels and effects in the body guide the first human dose and the final approved dosing schedule.
Talk
Mon Dec 14
5:15pm–5:45pm
Targeting IgE Responses
Track 2: Engineering Solutions for Accessing Difficult Targets
Beyond oncology
Chair
Wed Dec 16
8:10am–8:15am
Co-Chairs’ Remarks
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs · with Rondo Therapeutics
University of Southampton
Southampton, United Kingdom
Academic
Public research university whose Centre for Cancer Immunology works on antibody immunotherapy and Fc receptor biology.
Chair
Mon Dec 14
2:25pm–2:30pm
Co-Chairs’ Remarks
Track 2: Engineering Solutions for Accessing Difficult Targets · with Macaw Therapeutics
Talk
Mon Dec 14
4:45pm–5:15pm
Disulfide Engineering of Immunostimulatory Antibodies for Augmented Receptor Agonism and Immune Cell Stimulation
Adding chemical bridges between an antibody's two arms to lock its shape and make it switch on immune cells more strongly.
Protein engineering
Chair
Tue Dec 15
8:10am–8:15am
Co-Chairs' Remarks
Track 2: Antibody Engineering for Proximity-Based Approaches · with Chai Discovery
RT
Biotech
Develops bispecific T cell engagers, including co-stimulatory CD28 bispecifics, for solid tumors.
Chair
Sun Dec 13
9:00am–9:10am
Session Co-Chair Welcome and Opening Remarks
Short research talks by scientists within ten years of their graduate degree, plus career advice and time to meet peers.
with Chai Discovery
Chair
Tue Dec 15
2:25pm–2:30pm
Co-Chairs’ Remarks
Track 1: Engineering and Biological Principles for Cell Engagers · with National Cancer Institute
Talk
Tue Dec 15
2:30pm–3:00pm
Combination of Signal 1 and Signal 2 T Cell Engagers for Treatment of Ovarian Cancer
Pairing two antibodies that give T cells both of the signals they need, aiming at ovarian cancer that no longer responds to platinum drugs.
Chair
Wed Dec 16
8:10am–8:15am
Co-Chairs’ Remarks
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs · with Regeneron
Twist Bioscience
South San Francisco, CA
Reagents & consumablesEvent partner
Synthetic DNA company whose biopharma unit provides antibody libraries and antibody discovery and optimization services.
Booth
Exhibiting at Booth 200
Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm
Talk
Mon Dec 14
12:15pm–1:15pm
Scaling Wet-Lab Validation for AI-based Biologic Discovery
Why lab testing has become the bottleneck for AI antibody design, and how a shared model platform from Eli Lilly connects to it.
with Eli Lilly
AI & computational designAntibody discovery
Talk
Tue Dec 15
1:40pm–2:00pm
Screening in the Format You’ll Develop In: Cell-Free Expression of Full-Length IgG
Making full-length antibodies without cells at screening scale, and how their binding compares with the same antibodies made in mammalian cells.
Antibody discovery
Talk
Wed Dec 16
7:30am–8:00am
Engineering for Better Bispecifics: Introducing the B-Body® Platform
A two-target antibody design meant to assemble reliably, avoiding low yields and hard purification when production scales up.
Bispecifics & multispecificsDevelopability & CMC
Discovery platformsBronze sponsor
Fully human antibody discovery built on its Harbour Mice transgenic platforms for conventional and heavy-chain-only antibodies, offered as integrated discovery services.
Booth
Exhibiting at Booth 203
Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm
Talk
Mon Dec 14
1:45pm–2:15pm
A Fully Human, AI-native Discovery and Development Platform for Next-generation Modality Solutions
How fully human antibody mice combined with AI design feed immune cell engagers, brain-crossing antibodies, drug conjugates and other complex formats.
Antibody discoveryAI & computational design
Talk
Tue Dec 15
11:30am–12:00pm
VHH to Mice – With a Focus on In vivo Discovery/Screening Approaches for Therapeutic Discovery Applications
Why single-domain human antibodies from engineered mice suit CAR-T cells and T-cell engagers, and how testing for target-cell killing picks better candidates.
Bispecifics & multispecifics
City of Hope
Duarte, CA
Academic
Cancer research and treatment center with a graduate school.
Talk
Wed Dec 16
4:15pm–4:45pm
MPACT: Engineering the Fc–FcγR Interface for Plug-and-Play, Mixed-Valency Multispecific Antibodies
Using a chemical bond at a natural antibody contact point to snap extra targeting or immune-activating parts onto one antibody.
Bispecifics & multispecifics
Talk
Wed Dec 16
4:15pm–4:45pm
Turning up the Heat: Radioimmunoconjugates for Targeted Radiation Therapy
Using antibodies and smaller antibody pieces to carry radioactive atoms that both image and irradiate tumors.

Explore the full Antibody Engineering 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Diego. Leave your work email and we’ll be in touch.

Privacy

Download the full Antibody Engineering 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers in bispecifics & multispecifics

Tell us what you sell and we’ll find the people at organizations working on bispecifics & multispecifics most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse Antibody Engineering 2026 by

Exhibit hall

Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction